Research Programs Sample Clauses
Research Programs. Subject to and in accordance with the terms of this Agreement, during the Research Term, Isis and Biogen Idec will conduct two research programs, each under a separate mutually agreed plan. The first research program will cover research focused on enhancing the Parties’ knowledge of ASO pharmacokinetics and pharmacodynamics in the central and peripheral nervous systems (such program, the “Core Research Program” and the plan for such program, the “Core Research Plan”). The second research program will focus on the identification and validation of High Interest Targets, and the identification of ALS Targets, that are eligible to become Collaboration Targets (such program, the “Neurological Disease Research Program” and the plan for such program, the “Neurological Disease Research Plan”). Drafts of the Core Research Plan and the initial Neurological Disease Research Plan have been mutually agreed upon by the Parties in writing on or prior to the Effective Date. The Parties will finalize these initially agreed draft plans within [***] days after the Effective Date. Thereafter, the Parties will update such plans at least once before the beginning of each Calendar Year, and submit them to the Neurology JRC for its review and approval. Each update to the Neurological Disease Research Plan will include, at a minimum (i) the activities to support Target Sanction in the Calendar Year covered by such Neurological Disease Research Plan, (ii) any Neurological Disease research to support Collaboration Programs, and (iii) any ongoing work on High Interest Targets from prior Calendar Years. Notwithstanding the foregoing, neither Party will be required to complete any activities under the Core Research Plan or Neurological Disease Research Plan if such Party in good faith believes that such activities are not technically feasible given the then-current state of the art.
Research Programs. Without limiting Section 3.4.1, upon the completion or other termination of any Research Program, MedImmune shall, at its own expense, transfer and/or disclose to Kolltan all Know-How developed under such Research Program that is Controlled by MedImmune. Such transfers and disclosures shall be made (a) in any manner or form reasonably requested by Kolltan (provided, however, that any data included in such Know-How shall be transferred in the form in which MedImmune has collected or maintained such data prior to such transfer) and (b) at MedImmune’s expense.
Research Programs. Subject to and in accordance with the terms of this Agreement, Isis and AstraZeneca will conduct two research programs, each under a separate mutually agreed plan. The data generated from these two research programs will inform the Drug Discovery Programs.
Research Programs. During the Research Term, Biogen will be responsible for all Biogen Activities under the Core Research Program and Neurological Disease Research Program, and all costs and expenses associated therewith.
Research Programs. If the Parties are carrying out a Research Plan(s) in accordance with Article 4 for which the Research Term is ongoing, Immunocore shall have the right, on a Research Program-by-Research Program basis, exercisable by notice in writing to GNE within [***], to withdraw from any such Research Program.
8.2.1 In the event that Immunocore chooses not to withdraw from a Research Program, that Research Program shall continue until its completion in accordance with Article 4. For the avoidance of doubt, the activities under such continued Research Program on which the Parties have agreed to collaborate shall continue to be funded by the Parties equally.
8.2.2 In the event that Immunocore notifies GNE that it is withdrawing from a Research Program, GNE shall have the option to continue such Research Program at its sole cost. For the avoidance of doubt, the ongoing activities under such Research Program shall be carried out as originally allocated between the Parties but at GNE’s sole cost. Should GNE choose not to take over the conduct of any such Research Program, the Research Program shall be discontinued.
Research Programs. The Service Provider shall obtain the prior consent of the CCAC prior to implementing any research or student programs that relate to the Service Provider’s obligations under this Agreement, such consent not to be unreasonably withheld or delayed.
Research Programs. 5.1 UTMDACC hereby transfers and agrees to transfer to ZIOPHARM the TRANSFERRED RESEARCH PROGRAMS existing as of the EFFECTIVE DATE and grants LICENSEE the exclusive rights to use the RESEARCH PROGRAM TECHNOLOGY RIGHTS, subject to the retained rights in Sections 3.3 and 3.4, ARTICLE XIV, APPLICABLE LAW and any rights and consents of third parties. Promptly after the EFFECTIVE DATE, the parties agree to discuss in good faith the best manner to effectuate such transfers. In addition, subject to the retained rights in Sections 3.3 and 3.4, ARTICLE XIV, APPLICABLE LAW and any rights and consents of third parties, and to the best of its ability, UTMDACC will transfer to ZIOPHARM the TRANSFERRED RESEARCH PROGRAMS and transfer or license the RESEARCH PROGRAM TECHNOLOGY RIGHTS, under a research and development agreement to be negotiated and entered into between UTMDACC and LICENSEE (the “R&D AGREEMENT”). Pending the completion and execution of the R&D AGREEMENT and subject to the rights granted to LICENSEE in this AGREEMENT, UTMDACC shall continue with the conduct of the TRANSFERRED RESEARCH PROGRAMS in the normal course provided that UTMDACC will not enter into any new third party research or funding contracts with respect to the TRANSFERRED RESEARCH PROGRAMS without LICENSEE’s written consent.
5.2 During the three (3) year period commencing on the effective date of the R&D AGREEMENT, ZIOPHARM will fund research and development at UTMDACC related to the TRANSFERRED RESEARCH PROGRAMS in the minimum amounts of $15 million per year and maximum amounts of $20 million per year, provided, however, that (a) the scope and subject matter of such work will be agreed to in writing in advance among UTMDACC and LICENSEE; (b) subject to APPLICABLE LAW and the rights of third parties, the R&D AGREEMENT will provide LICENSEE with a right of first refusal with respect to an exclusive license for any intellectual property rights derived from the research conducted under the R&D AGREEMENT; and (c) the first $15 million of research funding shall be payable to UTMDACC in quarterly installments of $3.75 million each that will commence ninety (90) days after the EFFECTIVE DATE with each successive installment payable three months after the due date of the prior installment, but all such amounts paid to UTMDACC will be held by UTMDACC pending the execution of the R&D AGREEMENT and will be expended only in accordance with the R&D AGREEMENT and ZIOPHARMS’s approval.
Research Programs. VirBio hereby agrees to take a Commercial License for each of the Research Programs as set forth in Section 3.2.
Research Programs. During the applicable Research Term, on a Research Program-by-Research Program basis, the Parties shall conduct Research Collaboration Activities in accordance with applicable Research Plan for such Research Program and terms and conditions of this Agreement.
Research Programs. PRI agrees to conduct each of the Research Programs during the Research Term in accordance with the applicable Research Plan, as such Research Plan may be amended from time to time by the Research Committee. PRI shall use its best efforts in carrying out the Research Programs and will furnish the research staff, technical know-how, equipment, instruments, supplies and facilities necessary to carry out the Research Programs at its own expense. InterMune shall provide funding to support PRI's conduct of the Research Programs, as described in Section 5.
1. Title in any equipment purchased or manufactured in the performance of the Research Programs shall vest in PRI.